Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis | Zendy

JulieAnne G. McGregor | Zendy; Susan L. Hogan | Zendy; Elizabeth Kotzen | Zendy; Caroline J. Poulton | Zendy; Yichun Hu | Zendy; Roberto Negrete-López | Zendy; Jason M. Kidd | Zendy; Suzanne L. Katsanos | Zendy; Donna O. Bunch | Zendy; Patrick H. Nachman | Zendy; Ronald J. Falk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis

Author(s) -

JulieAnne G. McGregor,

Susan L. Hogan,

Elizabeth Kotzen,

Caroline J. Poulton,

Yichun Hu,

Roberto Negrete-López,

Jason M. Kidd,

Suzanne L. Katsanos,

Donna O. Bunch,

Patrick H. Nachman,

Ronald J. Falk

Publication year - 2015

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfv076

Subject(s) - rituximab , medicine , cyclophosphamide , anti neutrophil cytoplasmic antibody , granulomatosis with polyangiitis , vasculitis , gastroenterology , microscopic polyangiitis , immunology , surgery , chemotherapy , lymphoma , disease

Rituximab has been used in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) since 2003. Our objective was to describe outcomes and adverse events following rituximab since that time in an inception cohort.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research